全文获取类型
收费全文 | 1324684篇 |
免费 | 101929篇 |
国内免费 | 4219篇 |
专业分类
耳鼻咽喉 | 16780篇 |
儿科学 | 43454篇 |
妇产科学 | 36350篇 |
基础医学 | 196185篇 |
口腔科学 | 35870篇 |
临床医学 | 128806篇 |
内科学 | 255537篇 |
皮肤病学 | 26347篇 |
神经病学 | 110960篇 |
特种医学 | 48109篇 |
外国民族医学 | 366篇 |
外科学 | 183451篇 |
综合类 | 28735篇 |
现状与发展 | 1篇 |
一般理论 | 460篇 |
预防医学 | 113291篇 |
眼科学 | 28908篇 |
药学 | 98544篇 |
6篇 | |
中国医学 | 3096篇 |
肿瘤学 | 75576篇 |
出版年
2019年 | 11623篇 |
2018年 | 16299篇 |
2017年 | 12281篇 |
2016年 | 13242篇 |
2015年 | 15190篇 |
2014年 | 20792篇 |
2013年 | 32043篇 |
2012年 | 44226篇 |
2011年 | 46876篇 |
2010年 | 27065篇 |
2009年 | 24917篇 |
2008年 | 42707篇 |
2007年 | 45047篇 |
2006年 | 45159篇 |
2005年 | 43582篇 |
2004年 | 41552篇 |
2003年 | 39448篇 |
2002年 | 38213篇 |
2001年 | 60721篇 |
2000年 | 62347篇 |
1999年 | 51916篇 |
1998年 | 13683篇 |
1997年 | 12259篇 |
1996年 | 12158篇 |
1995年 | 12353篇 |
1994年 | 11567篇 |
1993年 | 10827篇 |
1992年 | 41479篇 |
1991年 | 40739篇 |
1990年 | 39422篇 |
1989年 | 37312篇 |
1988年 | 34540篇 |
1987年 | 33667篇 |
1986年 | 32118篇 |
1985年 | 30619篇 |
1984年 | 22990篇 |
1983年 | 19524篇 |
1982年 | 11690篇 |
1981年 | 10221篇 |
1979年 | 20759篇 |
1978年 | 14769篇 |
1977年 | 12014篇 |
1976年 | 11833篇 |
1975年 | 12081篇 |
1974年 | 14774篇 |
1973年 | 14452篇 |
1972年 | 13349篇 |
1971年 | 12408篇 |
1970年 | 11472篇 |
1969年 | 10402篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
72.
Malinda Itchins Brandon Lau Amanda L. Hudson Helen Westman Cathy Yi Xia Sarah A. Hayes Viive M. Howell Michael Rodriguez Wendy A. Cooper Heng Wei Michael Buckland Bob T. Li Mark Li Vivek Rathi Stephen B. Fox Anthony J. Gill Stephen J. Clarke Michael J. Boyer Nick Pavlakis 《The oncologist》2020,25(8):641-649
73.
M.S. Iqbal G. Vashisht R. McMenemin P. Atherton F. McDonald T. Simmons A. Bradshaw J. Kovarik H. Turnbull L. Dodd P. Mulvenna A. Greystoke 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):e1-e10
Aims
Concomitant chemoradiation is the standard of care in patients with inoperable non-small cell lung cancer. The purpose of this study was to analyse the survival outcome and toxicity data of using hypofractionated chemoradiation.Materials and methods
One hundred patients were treated from June 2011 to November 2016. Treatment consisted of 55 Gy in 20 daily fractions concurrently with split-dose cisplatin vinorelbine chemotherapy over 4 weeks followed by two cycles of cisplatin vinorelbine only. Survival was estimated using Kaplan–Meier and Cox regression was carried out for known prognostic factors. A systematic search of literature was conducted using Medline, Embase and Cochrane databases and relevant references included.Results
In total, 97% of patients completed radiotherapy and 73% of patients completed all four cycles of chemotherapy. One patient died of a cardiac event during consolidative chemotherapy. There were two cases of grade 4 toxicities (one sepsis, one renal impairment). Grade 3 toxicities included nausea/vomiting (17%), oesophagitis (15%), infection with neutropenia (12%) and pneumonitis (4%). Clinical benefit was seen in 86%. Two-year progression-free survival and overall survival rates were 49% and 58%, respectively. The median progression-free survival and overall survival were 23.4 and 43.4 months, respectively. The only significant prognostic factor was the number of chemotherapy cycles received (P = 0.02). The systematic review identified 13 relevant studies; a variety of regimens were assessed with variable reporting of outcomes and toxicity but with overall an improvement in survival over time.Conclusion
Our experience compared with the original phase II trial showed improved treatment completion rates and survival with acceptable morbidity. With appropriate patient selection this regimen is an effective treatment option for locally advanced non-small cell lung cancer. This study helps to benchmark efficacy and toxicity rates while considering the addition of new agents to hypofractionated concurrent chemoradiotherapy. The agreement of a standard regimen for assessment in future trials would be beneficial. 相似文献74.
75.
76.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
77.
Yu-Tzu Chan Alan C.-Y. Lai Ruey-Jen Lin Ya-Hui Wang Yi-Ting Wang Wen-Wei Chang Hsin-Yi Wu Yu-Ju Lin Wen-Ying Chang Jen-Chine Wu Jyh-Cherng Yu Yu-Ju Chen Alice L. Yu 《International journal of cancer. Journal international du cancer》2020,146(6):1674-1685
G protein-coupled estrogen receptor-1 (GPER), a member of the G protein-coupled receptor (GPCR) superfamily, mediates estrogen-induced proliferation of normal and malignant breast epithelial cells. However, its role in breast cancer stem cells (BCSCs) remains unclear. Here we showed greater expression of GPER in BCSCs than non-BCSCs of three patient-derived xenografts of ER−/PR+ breast cancers. GPER silencing reduced stemness features of BCSCs as reflected by reduced mammosphere forming capacity in vitro, and tumor growth in vivo with decreased BCSC populations. Comparative phosphoproteomics revealed greater GPER-mediated PKA/BAD signaling in BCSCs. Activation of GPER by its ligands, including tamoxifen (TMX), induced phosphorylation of PKA and BAD-Ser118 to sustain BCSC characteristics. Transfection with a dominant-negative mutant BAD (Ser118Ala) led to reduced cell survival. Taken together, GPER and its downstream signaling play a key role in maintaining the stemness of BCSCs, suggesting that GPER is a potential therapeutic target for eradicating BCSCs. 相似文献
78.
Bhavana Pothuri Allison L. Brodsky Joseph A. Sparano Stephanie V. Blank Mimi Kim Dawn L. Hershman Amy Tiersten Brian F. Kiesel Jan H. Beumer Leonard Liebes Franco Muggia 《Cancer chemotherapy and pharmacology》2020,85(4):741-751
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy. 相似文献
79.
L. Piram T. Frédéric-Moreau R. Bellini F. Martin J. Miroir N. Saroul N. Pham Dang J. Biau M. Lapeyre 《Cancer radiothérapie》2019,23(3):272-269
Salivary glands tumours are uncommon tumours showing a large diversity of histological types. This article presents a synthesis of patterns and paths of invasion of parotid glands tumours in order to propose an approach of the delineation of primary tumour clinical target volumes and of the selection of lymph nodes target volumes. This article does not discuss treatment indications but defines clinical target volumes to treat if radiotherapy is indicated. Postoperative situation being the most frequent, the delineation of primary tumour clinical target volume is based on an anatomical approach. 相似文献
80.
Imre W.K. Kouw Bart B.L. Groen Joey S.J. Smeets Irene Fleur Kramer Janneau M.X. van Kranenburg Rachél Nilwik Jan A.P. Geurts René H.M. ten Broeke Martijn Poeze Luc J.C. van Loon Lex B. Verdijk 《Journal of the American Medical Directors Association》2019,20(1):35-42